Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study

Fig. 2

Primary and secondary endpoints: (A) proportion of patients who achieved ACR20 at week 12. Baricitinib 4 mg in the evening resulted in better improvement than baricitinib 4 mg in the morning (p < 0.001). (B) Proportion of patients who achieved ACR20, (C) ACR50, and (D) ACR70 at weeks 4, 8, 12, 24, and 52. (i) Baricitinib 2 mg in the morning vs. baricitinib 2 mg in the evening, n = 50, 51 (ii) Baricitinib 4 mg in the morning vs. baricitinib 4 mg in the evening, n = 52, 53, respectively. Error bars represented a 95% confidence interval. ACR20, ACR50, and ACR70: 20%, 50%, and 70% improvement in American College of Rheumatology criteria

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us